bioAffinity appoints Jamie Platt to board; Mohsin Meghji resigns

bioAffinity Technologies, Inc.

Jamie Platt, Ph.D., appointed to board effective Dec. 1, 2023; also joins Compensation Committee.
Platt brings 20 years of genomics/diagnostics experience; led two M&A exits worth ~$1B combined.
Mohsin Meghji resigned same day for personal reasons, no disagreement with company.
Platt receives standard non-employee director compensation: $25k annual fee + quarterly restricted stock grant valued at $18,750.
She currently serves as CEO of Pictor Ltd. and President/CEO of BRIDGenomics.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mohsin Y. Meghji

Director

BIAF · bioAffinity Technologies, Inc.

Effective: 2023-12-01
Filed: December 5, 2023, 6:59 PM ET

On December 1, 2023 , Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.

Appointed

Jamie Platt

Director

BIAF · bioAffinity Technologies, Inc.

Effective: 2023-12-01
Filed: December 5, 2023, 6:59 PM ET

On December 1, 2023, the Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) appointed Jamie Platt, Ph.D., to serve as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mohsin Y. Meghji resigned as Director at bioAffinity Technologies, Inc..

Action: resigned
Role: Director

Exact text from the filing

On December 1, 2023 , Mohsin Y. Meghji resigned from the Board of Directors, effective immediately, for personal reasons, and not due to any disagreement with the Company or its operations, policies or practices.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jamie Platt was appointed as Director at bioAffinity Technologies, Inc..

Action: appointed
Role: Director

Exact text from the filing

On December 1, 2023, the Board of Directors (the “Board”) of bioAffinity Technologies, Inc. (the “Company”) appointed Jamie Platt, Ph.D., to serve as a director of the Company.

View on SEC.gov

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-043665

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.